- Home
- OMCC vs ANTX Comparison
OMCC vs ANTX Comparison
Compare OMCC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCC
- ANTX
- Stock Information
- Founded
- OMCC 1985
- ANTX 2017
- Country
- OMCC United States
- ANTX United States
- Employees
- OMCC N/A
- ANTX N/A
- Industry
- OMCC
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- OMCC
- ANTX Health Care
- Exchange
- OMCC NYSE
- ANTX Nasdaq
- Market Cap
- OMCC 36.8M
- ANTX 33.2M
- IPO Year
- OMCC N/A
- ANTX 2022
- Fundamental
- Price
- OMCC $5.60
- ANTX $1.06
- Analyst Decision
- OMCC
- ANTX Buy
- Analyst Count
- OMCC 0
- ANTX 2
- Target Price
- OMCC N/A
- ANTX $2.00
- AVG Volume (30 Days)
- OMCC 3.4K
- ANTX 74.8K
- Earning Date
- OMCC 08-25-2025
- ANTX 08-12-2025
- Dividend Yield
- OMCC N/A
- ANTX N/A
- EPS Growth
- OMCC N/A
- ANTX N/A
- EPS
- OMCC N/A
- ANTX N/A
- Revenue
- OMCC $9,366,000.00
- ANTX N/A
- Revenue This Year
- OMCC N/A
- ANTX N/A
- Revenue Next Year
- OMCC N/A
- ANTX N/A
- P/E Ratio
- OMCC N/A
- ANTX N/A
- Revenue Growth
- OMCC N/A
- ANTX N/A
- 52 Week Low
- OMCC $4.21
- ANTX $0.87
- 52 Week High
- OMCC $7.00
- ANTX $2.70
- Technical
- Relative Strength Index (RSI)
- OMCC N/A
- ANTX 43.83
- Support Level
- OMCC N/A
- ANTX $1.05
- Resistance Level
- OMCC N/A
- ANTX $1.09
- Average True Range (ATR)
- OMCC 0.00
- ANTX 0.03
- MACD
- OMCC 0.00
- ANTX -0.00
- Stochastic Oscillator
- OMCC 0.00
- ANTX 9.43
About OMCC OLD MARKET CAPITAL CORPORATION
Old Market Capital Corp is a specialized consumer finance company. The Company now operates as a holding company which indirectly owns a controlling interest in a broadband company. The Company announced the restructuring of its operation.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.